Business

Ocugen Inc. (NASDAQ: OCGN), Provention Bio Inc. (NASDAQ: PRVB), Contextlogic Inc. (NASDAQ: WISH), and Acasti Pharma Inc. (NASDAQ: ACST) under probe For Securities Laws Violation

Ocugen Inc. (NASDAQ: OCGN), Provention Bio Inc. (NASDAQ: PRVB), Contextlogic Inc. (NASDAQ: WISH), and Acasti Pharma Inc. (NASDAQ: ACST) are facing an investigation from various law firms on behalf of shareholders over potential securities laws violation. 

Contextlogic under probe 

Levi & Korsinsjy LLP is investigating Contextlogic on behalf of investors that purchased the company’s shares between December 16, 2020, and May 12, 2021, according to the registration statement and prospectus issued concerning the company’s December 16, 2020, IPO. Investors who lost money have up to July 16 to contact the law firm. The prospectus and registration statement the company used for the IPO had materially and false statements regarding the strength of its operations and financial potential. It overstated MAUs and growth trends. 

Provention offered a misleading statement about teplizumab BLA

Provention Bio is also under probe for offering materially false and misleading statements regarding the BLA for teplizumab. In addition, the company allegedly offered deficient information in its BLA, which the FDA said needed additional information to secure approval. Accordingly, investors who purchase the company’s stock between November 2, 2020, and April 8, 2021, should contact Levi & Korsinsky LLP by July 20, 2021. 

Levi and Korsinsky investigating Ocugen 

Ocugen is also under probe by Levi & Korsinsky LLP regarding the submission of materially false or misleading statements about its Emergency Use Authorization to the FDA. The company didn’t offer adequate information to support a EUA. As a result, it will not file the EUA. Accordingly, investors who bought OCGN between February 2, 2021, and June 10, 2021, should contact the law firm by August 17, 2021. 

Acasti is also under investigation regarding possible securities laws violation relating to the Grace Therapeutics merger. Investors should contact Halper Sadeh LLP regarding the investigation.

Leave a Comment

Your email address will not be published. Required fields are marked *

*